Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Dec;79(12):1317-1324.
doi: 10.1111/anae.16454. Epub 2024 Oct 22.

Relationship between residual gastric content and peri-operative semaglutide use assessed by gastric ultrasound: a prospective observational study

Rafael S F Nersessian  1   2 , Leopoldo M da Silva  1   2 , Marco Aurélio S Carvalho  2   3 , Saullo Q Silveira  3 , Arthur C V Abib  1 , Fernando N Bellicieri  1 , Helidea O Lima  2 , Anthony M-H Ho  4 , Gabriel S Anjos  1 , Glenio B Mizubuti  4
Affiliations
Observational Study

Relationship between residual gastric content and peri-operative semaglutide use assessed by gastric ultrasound: a prospective observational study

Rafael S F Nersessian et al. Anaesthesia. 2024 Dec.

Abstract

Background: Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist known to delay gastric emptying. Despite a growing body of evidence, its peri-operative safety profile remains uncertain, particularly with regard to the risk of increased residual gastric content and aspiration of gastric contents during anaesthesia. We hypothesised that semaglutide interruption of ≤ 10 days before elective surgical procedures is insufficient to reduce or normalise the residual gastric content, despite fasting intervals that comply with current guidelines.

Methods: In this prospective observational study, we recruited patients who received pre-operative once-weekly subcutaneous semaglutide within 10 days of the procedure (semaglutide group) and control patients who had not been exposed to semaglutide (non-semaglutide group). On the day of surgery, all patients underwent pre-operative point-of-care gastric ultrasound to evaluate their residual gastric content. Increased residual gastric content was defined as any solid content or > 1.5 ml.kg-1 of clear fluids as assessed by gastric ultrasound.

Results: We recruited 220 patients, 107 in the semaglutide group and 113 in the non-semaglutide group. Increased residual gastric content was found in 43/107 patients (40%) in the semaglutide group and 3/113 (3%) in the non-semaglutide group (p < 0.001). In propensity-weighted analysis, semaglutide use (OR 36.97, 95%CI 16.54-99.32), age (OR 0.95, 95%CI 0.93-0.98) and male sex (OR 2.28, 95%CI 1.29-4.06) were significantly associated with increased residual gastric content. There were no cases of pulmonary aspiration of gastric contents.

Conclusion: Pre-operative semaglutide use within 10 days of elective surgical procedures was independently associated with increased risk of residual gastric content on pre-operative gastric ultrasound assessment.

Keywords: aspiration of gastric contents; gastric ultrasound; point‐of‐care ultrasound; pre‐operative interruption interval; semaglutide.

PubMed Disclaimer

References

    1. Mizubuti GB, Ho AM‐H, da SLM, Phelan R. Perioperative management of patients on glucagon‐like peptide‐1 receptor agonists. Curr Opin Anaesthesiol 2024; 37: 323–333. https://doi.org/10.1097/ACO.0000000000001348.
    1. Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 2017; 19: 1242–1251. https://doi.org/10.1111/dom.12932.
    1. O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double‐blind, placebo and active controlled, dose‐ranging, phase 2 trial. Lancet 2018; 392: 637–649. https://doi.org/10.1016/s0140‐6736(18)31773‐2.
    1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834–1844. https://doi.org/10.1056/nejmoa1607141.
    1. American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2022. Diabetes Care 2022; 45: S125–S143. https://doi.org/10.2337/dc22‐s009.

Publication types

LinkOut - more resources